ZykadiaCyramzaFruzaqlaFruquintinibImfinzidurvalumabramucirumabBrigatinibceritinib
…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…
74articles mentioning drugs
192drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: AtEzolizumab ×
AtEzolizumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning AtEzolizumab
74 articles · page 2 of 7atezolizumabES-SCLCtertiary hospitalextensive-stage small-cell lung cancersolid tumoursanticancer immunotherapy
…er (ES-SCLC).Aim and Objectives To assess whether the timing of atezolizumab infusions (early vs late) is associated with efficacy in ES-SCL…
pembrolizumabDurvalumabdostarlimabatezolizumab
… therapeutic positioning.Aim and Objectives To evaluate whether pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezoli…
encorafenibvemurafenibbinimetinibcobimetinibdabrafenibNIVO+RELAatezolizumabnivolumabtrametinibNIVO+IPI
…TEZO, atezolizumab; BINI, binimetinib; COBI, cobimetinib; ENCO, encorafenib; ESS, effective sample size; DAB, dabrafenib; NIVO, nivolumab; …
atezolizumabAlomfilimabSAR445256KY1044advanced solid tumorsNational Comprehensive Cancer Network
…y cells, in both single-agent and in combination treatment with atezolizumab. This was accompanied by transient elevation of granulocyte-mac…
osimertinibcrizotinibsotorasibatezolizumabdurvalumablorlatinibosimertinib-treated
…ring may help identify patients who could benefit from extended osimertinib therapy, although further clinical validation is warranted.ctDN…
docetaxelpembrolizumabtislelizumabsitravatinib
…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…
durvalumabatezolizumabplatinum-etoposidetremelimumabextensive-stage small cell lung cancerextensive-stage small-cell lung cancerimmunotherapyfirst-line chemotherapyES-SCLC
…otherapy, 563 (87.4%) received atezolizumab; 61 (9.5%) received durvalumab. We found that the median OS was 9 months vs 7.2 months (p <0.0…
tarlatamabatezolizumabdurvalumabcarboplatinetoposideImdelltraES-SCLCsmall cell lung cancerMerck Sharp & Dohme LLC
…age small cell lung cancer. Oncologist 2021;26:433-8.Imdelltra (tarlatamab). Full Prescribing Information, Amgen Inc, Thousand Oaks, CA, U…
atezolizumabARPIMemorial Sloan Kettering Cancer Centerprostate cancermHSPC
…ade (ICB) and hormonal therapy/RT, we tested the combination of atezolizumab (PD-L1 blockade) plus ARPI, ADT and RT to the prostate in men w…
AtEzolizumabTIraGolumabRadScopalsolid tumorsMD Anderson Cancer Center
…herapy ( NCT02710253), and the Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malign…
atezolizumabbevacizumabAtezo+BevChiba University Hospitalhepatocellular carcinomaNational Institute for Quantum and Radiological Science and Technology, QST HospitalC-ion RTHCCradiotherapy
…ithin one calendar week. Patients will receive a combination of atezolizumab (1200 mg) and bevacizumab (15 mg/kg) administered intravenously…